Selected discussion
Efficacy and safety of Lianhua Qingwen versus oseltamivir in children with influenza a multicenter, randomized, double-blind, positive parallel-controlled study.
Clinical evidence update from Pharmaceutical biology
Clinical Context Peer-reviewed veterinary literature continues to shape everyday decision-making for production animal practice, especially when new evidence clarifies diagnosis, treatment selection, monitoring, or clinical outcomes.
What the Study Evaluated A study published in Pharmaceutical biology in 2026 evaluated efficacy and safety of Lianhua Qingwen versus oseltamivir in children with influenza: a multicenter, randomized, double-blind, positive parallel-controlled study..
Key Findings High-quality evidence on Lianhua Qingwen (LHQW) for treating influenza in children remains limited. To evaluate the efficacy and safety of LHQW in children aged 3-14 years with influenza, compared with oseltamivir. In this multicenter, randomized, double-blind, positive parallel-controlled trial, participants were randomly assigned (1:1) to receive either LHQW + oseltamivir placebo or oseltamivi…
Discussion thread
Community replies
Follow the line down to read the conversation in order.
No replies yet
No replies yet. Be the first professional to join this discussion.
Use the reply box above to start the conversation.


Join this discussion
Add your reply
Share a professional insight, ask a focused question, or add relevant clinical experience.
Member participation
Log in to join the discussion
Share an answer, ask a question, reply to another professional, or mark useful contributions as helpful.